Pacira Pharmaceuticals Inc (PCRX)

Debt-to-capital ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Long-term debt US$ in thousands 513,796 515,941 532,183 542,918 655,823 713,999 721,878 729,743 674,530 326,146 321,708 317,338 313,030 456,464 314,182 310,078 306,045 302,081 298,185 294,356
Total stockholders’ equity US$ in thousands 870,130 831,551 807,975 768,041 775,010 770,123 756,636 709,576 730,408 718,602 687,168 650,818 619,688 584,690 388,148 374,036 354,944 346,162 341,650 327,519
Debt-to-capital ratio 0.37 0.38 0.40 0.41 0.46 0.48 0.49 0.51 0.48 0.31 0.32 0.33 0.34 0.44 0.45 0.45 0.46 0.47 0.47 0.47

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $513,796K ÷ ($513,796K + $870,130K)
= 0.37

The debt-to-capital ratio of Pacira BioSciences Inc has been fluctuating over the past eight quarters, indicating the company's changing level of debt compared to its total capital. The ratio has generally been on a decreasing trend from Q1 2022 to Q4 2023, suggesting a potential improvement in the company's debt management and capital structure.

The ratio stood at its highest of 0.57 in Q1 2022, indicating that 57% of the company's capital was financed by debt at that time. Subsequently, the ratio gradually decreased to 0.38 in Q4 2023, demonstrating that only 38% of the company's capital was debt-funded in the most recent quarter.

This declining trend signifies that Pacira BioSciences Inc may have been reducing its reliance on debt as a source of capital over the quarters, which could be viewed positively by investors and creditors. However, it is essential to consider other financial metrics and industry benchmarks to gain a holistic understanding of the company's overall financial health and leverage position.